Thrivent Financial for Lutherans Decreases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Thrivent Financial for Lutherans trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,312 shares of the medical equipment provider’s stock after selling 435 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Lantheus were worth $1,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in LNTH. GAMMA Investing LLC grew its stake in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the last quarter. Signaturefd LLC increased its holdings in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the period. Nkcfo LLC purchased a new position in Lantheus during the 2nd quarter worth approximately $47,000. UMB Bank n.a. boosted its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in shares of Lantheus in the third quarter worth $51,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LNTH shares. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Redburn Atlantic started coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. Finally, JMP Securities cut their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Down 1.1 %

NASDAQ LNTH opened at $89.27 on Friday. The firm has a market cap of $6.21 billion, a P/E ratio of 15.02 and a beta of 0.51. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The business’s 50-day moving average price is $101.76 and its 200 day moving average price is $97.04.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.